EHA 2025 | MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma

MagnetisMM-6 is one of the first trials which is investigating the role of a bispecific monoclonal antibody anti-BCMA, elranatamab, in combination with lenalidomide and daratumumab in the frontline setting in newly diagnosed symptomatic patients with multiple myeloma who are not considered eligible for high dose therapy. This particular study had several cohorts and I am presenting at this meeting cohort G which is involving a combination of elranatamab at the dose of 76 milligrams given every four weeks with lenalidomide and daratumumab at regular doses. 

So with this cohort we saw that more than 90% of the patients achieved a very good partial response or better. The complete response rate is improving because we have a relatively short median follow-up of only a few months and this came with acceptable tolerability. We had the CRS in many patients but it was grade one. We used regularly immunoglobulins and this led to a decreased incidence of severe infections. And we believe that this combination will move ahead to be compared with the standard of care which is a combination of lenalidomide, daratumumab and dexamethasone. So MagnetisMM-6 gives the opportunity of a bispecific-based combination, especially with elranatamab, to be evaluated in a prospective trial as a frontline therapy for elderly patients with multiple myeloma.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.